Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 28;11(2):e006234. doi: 10.1136/jitc-2022-006234

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Construction of a spatially resolved signature to predict clinical response to immunotherapy. Boxplot of signature scores from stromal (A) and tumor regions (B) between different response groups. (C) ROC curves of efficacy prediction of constructed signatures in the stromal, tumor regions, as well as traditional biomarkers PD-L1 and TMB. (D) Survival curves of the PFS prognostic value of the stroma signature. (E) Survival curves of the OS prognostic value of the stroma signature. (F) Box plot of efficacy prediction of signature constructed by genes corresponding to differential proteins between different response groups in a validation cohort. (G) ROC of gene signature in the validation cohort. (H) Survival curves showed the PFS prognostic value of gene signature in validation cohort. (I) Survival curves showed the OS prognostic value of gene signature in validation cohort. mPFS, median progression-free survival; NR, not reached; OS, overall survival; PD, progressive disease; PD-L1, programmed death ligand-1; PFS, progression-free survival; PR, partial response; ROC, receiver operating characteristic; TMB, tumor mutation burden.